摘要
目的系统评价我国慢性前列腺炎（chronicprostatitis,CP）治疗的有效性与安全性。方法计算机检索MEDLINE（1966-2007.5）、EMbase（1988-2007.5）、中国生物医学文献光盘数据（1979-2007.5）、中国生物医学期刊文献数据库（CMCC,1979-2007.5）、CNKI数字图书馆（1979-2007.5）,手工检索《中华泌尿外科杂志》等5种相关杂志,纳入与CP治疗有效性和安全性有关的临床随机对照试验,并追索已纳入文献的参考文献。由两名系统评价员独立进行文献筛查、质量评价和资料提取,并交叉核对,意见不一致时通过讨论或向专家咨询解决。Meta分析采用RevMan4.2软件。结果共初检出412篇文献,经筛选后最后纳入9篇RCT（917例）进行分析。Meta分析结果显示：与安慰剂相比,前列安栓、翁沥通、川参通、α受体阻滞剂、黄酮哌酯、舍尼通均能减少NIH-CPSI总计得分[RR1.99,95%CI（1.60,2.48）;RR2.7695%CI（2.13,3.57）;RR2.49,95%CI（1.24,4.97）;WMD-5.90,95%CI（-8.12,-3.68）;WMD-2.50,95%CI（-4.85,-0.15）;WMD-6.07,95%CI（-7.92,-4.22）]。α受体阻滞剂、翁沥通、黄酮哌酯、舍尼通与安慰剂比较,也能降低疼痛评分。结论药物干预治疗能一定程度上改善CP患者总的NIH-CPSI评分和总体症状,但不能改善所有症状;今后的临床研究需选择适宜样本量和最佳疗程,并进行随访;同时提高国内原始研究质量,开展高质量临床研究非常重要。
Objective To evaluate the efficacy and safety of the treatment of chronicprostatitis（CP） in China. Methods We search the related original studies about the treatment for Chinese CPall over the world,and only included randomized controlled trials （RCTs）. MEDLINE（1966-2007.5）, PubMed （1966-2007.5）, EMBASE（1988-2007.05）, and four Chinese databases were electronically searched and 6 related journals were handsearched. The studies included in the references of eligible studies were additionally searched. Two reviewers independently screened the studies for eligibility, evaluated the quality and extracted the data from the eligible studies,with confirmation by cross-checking. Divergences of opinion were settled by discussion or consulted by the expert. Meta-analysis was performed by using Rev Man 4.2 software. Results Nine original studies involving 917 participants met inclusion criteria. Compared with placebo, prostant,Wengl itong,Chuanshentong,alpha-blockers, bioflabonoid and porstat could reduce the NIH-chronic prostatitis symptom indexIRR1.99,95% CI （ 1.60,2.48 ）; RR2.76 95%,6 CI（2.13, 3.57）; RR2.49, 95% CI（1.24,4.97） ; WMD -5.90, 95%CI （-8.12,-3.68 ）; WMD -2.50, 95%CI （-4.85,-0.15 ）; WMD -6.07, 95%CI（-7.92, -4.22）]. Alpha-blockers,Wenglitong, bioflabonoid and porstat can also reduce the symtom index of pain.Conclusion Drug interventions could improve NIH- CPSI and total symptoms of CPin some degree, but can not improve all symptoms,future RCTs must use an appropriate sample size and optimal duration and follow-up of participants. It is important to improve the quality of internal original studies.
出处
《中国循证医学杂志》
CSCD
2007年第10期737-742,共6页
Chinese Journal of Evidence-based Medicine
